N. S. Ardashirova, N. Abramycheva, E. Fedotova, V. Sukhorukov, A. Voronkova, N. Mudzhiri, S. Illarioshkin
{"title":"利用多重基因表达分析鉴定与帕金森病相关的RNA标记","authors":"N. S. Ardashirova, N. Abramycheva, E. Fedotova, V. Sukhorukov, A. Voronkova, N. Mudzhiri, S. Illarioshkin","doi":"10.54101/acen.2022.4.5","DOIUrl":null,"url":null,"abstract":"Introduction. Parkinson's disease (PD) is a neurodegenerative disorder, and the development of biomarkers is essential due to complicated PD diagnosis and progression assessment. \nObjective. To identify PD RNA markers by multiplex expression profiling of 760 genes associated with the main neuropathological processes. \nMaterials and methods. We studied the expression of 760 genes associated with the main neuropathological processes using Nanostring nCounter Human Neuropathology Panel in 29 blood samples obtained from PD patients, including 13 samples from those in the early stage and 16 samples from those in the advanced stage, and in 16 control blood samples. \nResults. The comparison of gene expression in the patients with early PD and in the controls demonstrated differential expression of genes CDKN1A and CPT1B. The comparison of gene expression in the patients with advanced PD and in the controls showed LRP1 upregulation in the advanced PD group. We also revealed СPT1B upregulation in advanced disease, with a positive correlation between СPT1B expression and PD duration. \nDiscussion. The variably expressed genes may be relevant as PD biomarkers for diagnosis and progression assessment.","PeriodicalId":36946,"journal":{"name":"Annals of Clinical and Experimental Neurology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of RNA markers associated with Parkinson's disease using multiplex gene expression analysis\",\"authors\":\"N. S. Ardashirova, N. Abramycheva, E. Fedotova, V. Sukhorukov, A. Voronkova, N. Mudzhiri, S. Illarioshkin\",\"doi\":\"10.54101/acen.2022.4.5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. Parkinson's disease (PD) is a neurodegenerative disorder, and the development of biomarkers is essential due to complicated PD diagnosis and progression assessment. \\nObjective. To identify PD RNA markers by multiplex expression profiling of 760 genes associated with the main neuropathological processes. \\nMaterials and methods. We studied the expression of 760 genes associated with the main neuropathological processes using Nanostring nCounter Human Neuropathology Panel in 29 blood samples obtained from PD patients, including 13 samples from those in the early stage and 16 samples from those in the advanced stage, and in 16 control blood samples. \\nResults. The comparison of gene expression in the patients with early PD and in the controls demonstrated differential expression of genes CDKN1A and CPT1B. The comparison of gene expression in the patients with advanced PD and in the controls showed LRP1 upregulation in the advanced PD group. We also revealed СPT1B upregulation in advanced disease, with a positive correlation between СPT1B expression and PD duration. \\nDiscussion. The variably expressed genes may be relevant as PD biomarkers for diagnosis and progression assessment.\",\"PeriodicalId\":36946,\"journal\":{\"name\":\"Annals of Clinical and Experimental Neurology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical and Experimental Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54101/acen.2022.4.5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Multidisciplinary\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Experimental Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54101/acen.2022.4.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Multidisciplinary","Score":null,"Total":0}
引用次数: 0
摘要
介绍。帕金森病(PD)是一种神经退行性疾病,由于其诊断和进展评估的复杂性,生物标志物的开发至关重要。目标。通过760个与主要神经病理过程相关的基因的多重表达谱鉴定PD RNA标记物。材料和方法。我们使用Nanostring nCounter Human Neuropathology Panel研究了PD患者29份血样中760个主要神经病理过程相关基因的表达,其中包括13份早期血样和16份晚期血样,以及16份对照血样。结果。早期PD患者与对照组的基因表达比较显示CDKN1A和CPT1B基因表达存在差异。晚期PD患者与对照组的基因表达比较显示,晚期PD组LRP1表达上调。我们还发现СPT1B在晚期疾病中上调,СPT1B的表达与PD持续时间呈正相关。讨论。可变表达基因可能作为PD诊断和进展评估的生物标志物。
Identification of RNA markers associated with Parkinson's disease using multiplex gene expression analysis
Introduction. Parkinson's disease (PD) is a neurodegenerative disorder, and the development of biomarkers is essential due to complicated PD diagnosis and progression assessment.
Objective. To identify PD RNA markers by multiplex expression profiling of 760 genes associated with the main neuropathological processes.
Materials and methods. We studied the expression of 760 genes associated with the main neuropathological processes using Nanostring nCounter Human Neuropathology Panel in 29 blood samples obtained from PD patients, including 13 samples from those in the early stage and 16 samples from those in the advanced stage, and in 16 control blood samples.
Results. The comparison of gene expression in the patients with early PD and in the controls demonstrated differential expression of genes CDKN1A and CPT1B. The comparison of gene expression in the patients with advanced PD and in the controls showed LRP1 upregulation in the advanced PD group. We also revealed СPT1B upregulation in advanced disease, with a positive correlation between СPT1B expression and PD duration.
Discussion. The variably expressed genes may be relevant as PD biomarkers for diagnosis and progression assessment.